← Calendar
Readoutin 45d
Novo Nordisk A/S — Ziltivekimab
Phase 3 primary completion: ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack.
- Date
- Jan 2027
- Type
- Readout
- Indication
- Cardiovascular Risk
Source ↗Add to calendar
Get told when this date moves
The weekly brief is free. Pro adds reminders 7 days and 1 day before.
More from Novo Nordisk A/S
May2027
Readoutin 165d
Novo Nordisk A/S — CagrilintidePhase 3 primary completion: Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide.
Mar2027
Readoutin 104d
Novo Nordisk A/S — CagriSema (Cagrilintide B and Semaglutide I)Phase 3 primary completion: A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term.
Jan2027
Readoutin 45d
Novo Nordisk A/S — Insulin icodecPhase 3 primary completion: A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes.